Navigation Links
Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Date:9/3/2009

SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, 2009 at 9:10 a.m. ET / 6:10 a.m. PT in New York. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... NY (PRWEB) , ... January 20, 2017 , ... Nipro ... a Joint Venture (JV) under which Nipro will receive exclusive marketing and sales rights ... to establish best practices for hemodialysis patients in Japan, the new Nipro - Transonic ...
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... Kan. , Jan. 20, 2017 Aratana ... therapeutics company focused on the licensing, development and commercialization ... Animal Pharm,s Best Company in North ... granted the award based on the FDA ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) ...
(Date:1/20/2017)... ... 2017 , ... The two newest companies to join the University City Science ... out from The Wistar Institute, and Sanguis, launched by a trio of students from ... , Vironika is developing a treatment for a chronic viral infection and its associated ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):